Cargando…

Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS

AIM: Over recent years, [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, which requires accurate values of rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Rumiantcev, Mikhail, Li, Wei Bo, Lindner, Simon, Liubchenko, Grigory, Resch, Sandra, Bartenstein, Peter, Ziegler, Sibylle I., Böning, Guido, Delker, Astrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495309/
https://www.ncbi.nlm.nih.gov/pubmed/37695374
http://dx.doi.org/10.1186/s40658-023-00567-2
_version_ 1785104865056260096
author Rumiantcev, Mikhail
Li, Wei Bo
Lindner, Simon
Liubchenko, Grigory
Resch, Sandra
Bartenstein, Peter
Ziegler, Sibylle I.
Böning, Guido
Delker, Astrid
author_facet Rumiantcev, Mikhail
Li, Wei Bo
Lindner, Simon
Liubchenko, Grigory
Resch, Sandra
Bartenstein, Peter
Ziegler, Sibylle I.
Böning, Guido
Delker, Astrid
author_sort Rumiantcev, Mikhail
collection PubMed
description AIM: Over recent years, [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, which requires accurate values of relative biological effectiveness (RBE). To achieve that, consideration of DNA damages in the cell nucleus and knowledge of the energy deposition in the location of the DNA at the nanometer scale are required. Monte Carlo particle track structure simulations provide access to interactions at this level. The aim of this study was to estimate the RBE of (225)Ac compared to (177)Lu. The initial damage distribution after radionuclide decay and the residual damage after DNA repair were considered. METHODS: This study employed the TOol for PArtcile Simulation (TOPAS) based on the Geant4 simulation toolkit. Simulation of the nuclear DNA and damage scoring were performed using the TOPAS-nBio extension of TOPAS. DNA repair was modeled utilizing the Python-based program MEDRAS (Mechanistic DNA Repair and Survival). Five different cell geometries of equal volume and two radionuclide internalization assumptions as well as two cell arrangement scenarios were investigated. The radionuclide activity (number of source points) was adopted based on SPECT images of patients undergoing the above-mentioned therapies. RESULTS: Based on the simulated dose–effect curves, the RBE of (225)Ac compared to (177)Lu was determined in a wide range of absorbed doses to the nucleus. In the case of spherical geometry, 3D cell arrangement and full radionuclide internalization, the RBE based on the initial damage had a constant value of approximately 2.14. Accounting for damage repair resulted in RBE values ranging between 9.38 and 1.46 for (225)Ac absorbed doses to the nucleus between 0 and 50 Gy, respectively. CONCLUSION: In this work, the consideration of DNA repair of the damage from [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA revealed a dose dependency of the RBE. Hence, this work suggested that DNA repair is an important aspect to understand response to different radiation qualities. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40658-023-00567-2.
format Online
Article
Text
id pubmed-10495309
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104953092023-09-13 Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS Rumiantcev, Mikhail Li, Wei Bo Lindner, Simon Liubchenko, Grigory Resch, Sandra Bartenstein, Peter Ziegler, Sibylle I. Böning, Guido Delker, Astrid EJNMMI Phys Original Research AIM: Over recent years, [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, which requires accurate values of relative biological effectiveness (RBE). To achieve that, consideration of DNA damages in the cell nucleus and knowledge of the energy deposition in the location of the DNA at the nanometer scale are required. Monte Carlo particle track structure simulations provide access to interactions at this level. The aim of this study was to estimate the RBE of (225)Ac compared to (177)Lu. The initial damage distribution after radionuclide decay and the residual damage after DNA repair were considered. METHODS: This study employed the TOol for PArtcile Simulation (TOPAS) based on the Geant4 simulation toolkit. Simulation of the nuclear DNA and damage scoring were performed using the TOPAS-nBio extension of TOPAS. DNA repair was modeled utilizing the Python-based program MEDRAS (Mechanistic DNA Repair and Survival). Five different cell geometries of equal volume and two radionuclide internalization assumptions as well as two cell arrangement scenarios were investigated. The radionuclide activity (number of source points) was adopted based on SPECT images of patients undergoing the above-mentioned therapies. RESULTS: Based on the simulated dose–effect curves, the RBE of (225)Ac compared to (177)Lu was determined in a wide range of absorbed doses to the nucleus. In the case of spherical geometry, 3D cell arrangement and full radionuclide internalization, the RBE based on the initial damage had a constant value of approximately 2.14. Accounting for damage repair resulted in RBE values ranging between 9.38 and 1.46 for (225)Ac absorbed doses to the nucleus between 0 and 50 Gy, respectively. CONCLUSION: In this work, the consideration of DNA repair of the damage from [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA revealed a dose dependency of the RBE. Hence, this work suggested that DNA repair is an important aspect to understand response to different radiation qualities. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40658-023-00567-2. Springer International Publishing 2023-09-11 /pmc/articles/PMC10495309/ /pubmed/37695374 http://dx.doi.org/10.1186/s40658-023-00567-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Rumiantcev, Mikhail
Li, Wei Bo
Lindner, Simon
Liubchenko, Grigory
Resch, Sandra
Bartenstein, Peter
Ziegler, Sibylle I.
Böning, Guido
Delker, Astrid
Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
title Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
title_full Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
title_fullStr Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
title_full_unstemmed Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
title_short Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS
title_sort estimation of relative biological effectiveness of (225)ac compared to (177)lu during [(225)ac]ac-psma and [(177)lu]lu-psma radiopharmaceutical therapy using topas/topas-nbio/medras
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495309/
https://www.ncbi.nlm.nih.gov/pubmed/37695374
http://dx.doi.org/10.1186/s40658-023-00567-2
work_keys_str_mv AT rumiantcevmikhail estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT liweibo estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT lindnersimon estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT liubchenkogrigory estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT reschsandra estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT bartensteinpeter estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT zieglersibyllei estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT boningguido estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras
AT delkerastrid estimationofrelativebiologicaleffectivenessof225accomparedto177luduring225acacpsmaand177lulupsmaradiopharmaceuticaltherapyusingtopastopasnbiomedras